Matches in SemOpenAlex for { <https://semopenalex.org/work/W2400548204> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2400548204 endingPage "75" @default.
- W2400548204 startingPage "267" @default.
- W2400548204 abstract "A clinical trial using interferon alpha 2b (IFN alpha-2b) for prophylactic therapy was done on 44 patients who had received nephrectomy for renal cell carcinoma. Principally, the daily intramuscular injection of 3 of 6 million units of IFN alpha-2b was done for 4 consecutive weeks after 2 weeks postoperatively and thereafter followed by injection once every 2 weeks. The clinical evaluation was done for the recurrence rate, the survival rate, the IFN alpha and IFN gamma producing ability, the activity of 2',5' oligoadenylate synthetase (2-5AS) and the side effect. Out of 44 cases entered, 42 were completely evaluable and recurrence was observed in 5 (11.9%) of the 42 cases. The recurrence rate was 5.5% and 16.4%, at the first and second year, respectively. Three (7.1%) of the 42 patients died. The survival rate was 97.6% at the first year, 89.7% at the second year for the followup study. The IFN alpha producing capacity was low in all of the 4 evaluable cases. The IFN gamma producing capacity was high in 3 cases and normal in 1 case. 2-5AS, the enzyme produced by IFN, was activated by IFN alpha-2b administration in all of the 4 evaluable cases. Side effects were observed in 24 (54.5%) of the 44 cases. The main side effect was fever. Leucopenia, general fatigue, appetite loss, temporary elevation of liver transaminase were also observed. However, there were only 5 cases (11.4%) in which administration of IFN alpha-2b had to be discontinued." @default.
- W2400548204 created "2016-06-24" @default.
- W2400548204 creator A5028074793 @default.
- W2400548204 creator A5034806502 @default.
- W2400548204 creator A5039509373 @default.
- W2400548204 creator A5054611582 @default.
- W2400548204 creator A5063089759 @default.
- W2400548204 creator A5063735719 @default.
- W2400548204 creator A5064293462 @default.
- W2400548204 creator A5073461841 @default.
- W2400548204 creator A5082294819 @default.
- W2400548204 creator A5088396071 @default.
- W2400548204 date "1992-03-01" @default.
- W2400548204 modified "2023-09-25" @default.
- W2400548204 title "[Clinical study of prophylactic therapy of interferon on postoperative renal cell carcinoma]." @default.
- W2400548204 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1523980" @default.
- W2400548204 hasPublicationYear "1992" @default.
- W2400548204 type Work @default.
- W2400548204 sameAs 2400548204 @default.
- W2400548204 citedByCount "0" @default.
- W2400548204 crossrefType "journal-article" @default.
- W2400548204 hasAuthorship W2400548204A5028074793 @default.
- W2400548204 hasAuthorship W2400548204A5034806502 @default.
- W2400548204 hasAuthorship W2400548204A5039509373 @default.
- W2400548204 hasAuthorship W2400548204A5054611582 @default.
- W2400548204 hasAuthorship W2400548204A5063089759 @default.
- W2400548204 hasAuthorship W2400548204A5063735719 @default.
- W2400548204 hasAuthorship W2400548204A5064293462 @default.
- W2400548204 hasAuthorship W2400548204A5073461841 @default.
- W2400548204 hasAuthorship W2400548204A5082294819 @default.
- W2400548204 hasAuthorship W2400548204A5088396071 @default.
- W2400548204 hasConcept C126322002 @default.
- W2400548204 hasConcept C141071460 @default.
- W2400548204 hasConcept C199360897 @default.
- W2400548204 hasConcept C203014093 @default.
- W2400548204 hasConcept C2776178377 @default.
- W2400548204 hasConcept C2776283816 @default.
- W2400548204 hasConcept C2776291583 @default.
- W2400548204 hasConcept C2777472916 @default.
- W2400548204 hasConcept C2777546739 @default.
- W2400548204 hasConcept C2780091579 @default.
- W2400548204 hasConcept C2780227381 @default.
- W2400548204 hasConcept C2909179924 @default.
- W2400548204 hasConcept C3454156 @default.
- W2400548204 hasConcept C41008148 @default.
- W2400548204 hasConcept C71924100 @default.
- W2400548204 hasConcept C90924648 @default.
- W2400548204 hasConceptScore W2400548204C126322002 @default.
- W2400548204 hasConceptScore W2400548204C141071460 @default.
- W2400548204 hasConceptScore W2400548204C199360897 @default.
- W2400548204 hasConceptScore W2400548204C203014093 @default.
- W2400548204 hasConceptScore W2400548204C2776178377 @default.
- W2400548204 hasConceptScore W2400548204C2776283816 @default.
- W2400548204 hasConceptScore W2400548204C2776291583 @default.
- W2400548204 hasConceptScore W2400548204C2777472916 @default.
- W2400548204 hasConceptScore W2400548204C2777546739 @default.
- W2400548204 hasConceptScore W2400548204C2780091579 @default.
- W2400548204 hasConceptScore W2400548204C2780227381 @default.
- W2400548204 hasConceptScore W2400548204C2909179924 @default.
- W2400548204 hasConceptScore W2400548204C3454156 @default.
- W2400548204 hasConceptScore W2400548204C41008148 @default.
- W2400548204 hasConceptScore W2400548204C71924100 @default.
- W2400548204 hasConceptScore W2400548204C90924648 @default.
- W2400548204 hasIssue "3" @default.
- W2400548204 hasLocation W24005482041 @default.
- W2400548204 hasOpenAccess W2400548204 @default.
- W2400548204 hasPrimaryLocation W24005482041 @default.
- W2400548204 hasRelatedWork W2021256410 @default.
- W2400548204 hasRelatedWork W2041698974 @default.
- W2400548204 hasRelatedWork W2113493650 @default.
- W2400548204 hasRelatedWork W2116661424 @default.
- W2400548204 hasRelatedWork W2315442029 @default.
- W2400548204 hasRelatedWork W2320030716 @default.
- W2400548204 hasRelatedWork W2400548204 @default.
- W2400548204 hasRelatedWork W2414688308 @default.
- W2400548204 hasRelatedWork W2416574063 @default.
- W2400548204 hasRelatedWork W2437081767 @default.
- W2400548204 hasVolume "38" @default.
- W2400548204 isParatext "false" @default.
- W2400548204 isRetracted "false" @default.
- W2400548204 magId "2400548204" @default.
- W2400548204 workType "article" @default.